Bristol-Myers Gets Europe OK for Sprycel in Form of Leukemia

Date : 02/11/2019 @ 12:47PM
Source : Dow Jones News
Stock : Bristol-Myers Squibb Company (BMY)
Quote : 45.77  0.0 (0.00%) @ 1:00AM

Bristol-Myers Gets Europe OK for Sprycel in Form of Leukemia

Bristol Myers Sqibb (NYSE:BMY)
Historical Stock Chart

6 Months : From Dec 2018 to Jun 2019

Click Here for more Bristol Myers Sqibb Charts.
   By Colin Kellaher 

Bristol-Myers Squibb Co. (BMY) on Monday said the European Commission approved the company's Sprycel in combination with chemotherapy for children with a form of leukemia.

The New York biopharmaceutical company said the approval covers the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia and includes both the tablet and powder formulations.

Bristol-Myers said the approval marks the second pediatric leukemia indication for Sprycel in Europe.


Write to Colin Kellaher at


(END) Dow Jones Newswires

February 11, 2019 07:32 ET (12:32 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest BMY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.